CO-ALEPH-OBJECTS-INC
Aleph Objects, Inc., is organizing for growth as 3D printing technology and its market segments continue to expand. The company, manufacturer of the reliable, award-winning LulzBot® 3D Printers , announced new roles for two executive team members this week.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181220005175/en/
Grant Flaharty, Aleph Objects, Inc. President, is stepping into the role of CEO in addition to his existing role. With over 20 years of executive experience, Flaharty is uniquely qualified to lead Aleph Objects through this evolving and increasingly demanding market in additive manufacturing technology. “The changes we are incorporating will drive significant growth as we rapidly expand our products, our reseller network, and our social presence into global markets. We are anticipating a record-breaking year with a larger percentage of business being received from outside the US,” Flaharty said. “The response rate for LulzBot’s high quality workhorse 3D printers is setting the bar for growth going forward.”
Steven Abadie, who has been with Aleph Objects since its launch in 2011, will be leveraging his expertise in 3D printing technology in his new position as CTO. His primary focus will be on driving the company’s development efforts in terms of new and innovative products. “We are working towards significant leaps in technology and design across our product line,” Abadie said. “In 2019, we expect to make a strong statement with new product offerings, all with a continued focus on Free Software, Libre Innovation, and Open Source Hardware.”
Aleph Objects’ user base has evolved to encompass enterprise and professional markets, and the trend is expected to continue as the technology becomes more sophisticated and accessible. “Additive manufacturing technology just keeps expanding at a mind-blowing rate,” said Jeff Moe, Aleph Objects, Inc. Founder. “The internal re-alignment of the company will ultimately serve to maintain a stronger focus on new product introduction going into this period of massive growth.”
https://www.youtube.com/watch?v=EAMr3jjEqUs
About Aleph Objects, Inc.
Aleph Objects, Inc. is the Colorado-based designer and manufacturer of the award-winning line of LulzBot® 3D Printers for rapid prototyping, additive manufacturing, educators, and hobbyists. Aleph Object’s core company values of Free Software, Libre Innovation, and Open Source Hardware enable users to uniquely modify both software and hardware to bring their imagination into reality. For more information, visit LulzBot.com /.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181220005175/en/
./ContentItem/Format ./ContentItem/MimeType ./ContentItem/Characteristics/Property LulzBot Platform of 3D Printers and Tool Heads 13555 169848 57326534 12246 4683Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release
-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 11:15:00 CET | Press release
AI-as-a-Service applications will make AI virtual CFO and COO for SMEsPublic-private collaboration in regulatory sandboxes help to provide clarity and certainty when it comes to new technology like tokenisation and AI Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on Novem
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 07:16:00 CET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 07:00:00 CET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
